Equities

Xencor Inc

Xencor Inc

Actions
  • Price (USD)22.13
  • Today's Change-0.29 / -1.29%
  • Shares traded525.55k
  • 1 Year change-20.57%
  • Beta0.7621
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

  • Revenue in USD (TTM)168.34m
  • Net income in USD-126.09m
  • Incorporated2004
  • Employees280.00
  • Location
    Xencor Inc465 N. HALSTEAD ST., SUITE 200PASADENA 91107United StatesUSA
  • Phone+1 (626) 305-5900
  • Fax+1 (626) 305-0350
  • Websitehttps://xencor.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tarsus Pharmaceuticals Inc17.45m-135.89m1.30bn244.00--6.00--74.29-4.58-4.580.59395.760.0707--1.6471,504.10-55.09-31.56-61.63-33.8290.87---778.89-242.596.85--0.1315---32.42---118.86--279.39--
Collegium Pharmaceutical Inc566.77m48.16m1.31bn197.0046.376.676.622.310.88230.882312.536.130.48916.103.132,876,990.004.162.796.754.8057.5550.888.505.161.102.590.77340.0022.1715.11292.60---54.77--
AbCellera Biologics Inc38.03m-146.40m1.31bn586.00--1.13--34.57-0.5062-0.50620.13153.960.0251--1.1064,890.79-9.676.08-10.496.67-----384.9924.697.32--0.000.00-92.1733.91-192.35--70.96--
Gyre Therapeutics Inc0.00-44.24m1.34bn7.00---------20.60-20.600.001.390.00----0.00-215.90-58.25-235.61-72.12-------817.06----0.00---89.18-4.8590.63------
Ironwood Pharmaceuticals, Inc.442.74m-1.00bn1.35bn267.00------3.05-6.51-6.512.59-2.210.5634--3.621,658,184.00-131.28-4.54-162.45-5.20-----233.00-7.81--63.791.98--7.835.02-672.50--160.10--
Pacira Biosciences Inc674.98m41.96m1.35bn711.0042.781.5511.482.000.67890.678912.3318.720.41471.846.62949,336.102.583.352.793.9872.6472.636.228.574.179.850.37520.001.2214.88163.72--0.8761--
Prothena Corporation PLC91.37m-147.03m1.35bn173.00--2.41--14.79-2.80-2.801.6810.460.1256----528,150.30-20.22-14.20-21.82-15.11-----160.92-111.02----0.00--69.50148.98-25.72--9.71--
Spyre Therapeutics Inc886.00k-338.79m1.35bn30.00------1,528.43-75.04-75.040.12857.450.0043--4.7329,533.33-164.06-101.87-184.94-118.83-----38,238.15-2,949.59----0.00---61.96-25.61-304.21------
Immunome Inc10.19m-21.96m1.36bn37.00--51.25--133.34-1.80-1.800.83690.49790.1648----275,459.50-35.50---47.11-------215.44------0.00-------51.83------
Vir Biotechnology Inc86.18m-615.06m1.36bn587.00--0.856--15.83-4.59-4.590.642511.800.0365----146,814.30-26.06-0.6081-30.49-0.719296.79---713.76-1.53----0.00---94.6751.87-219.24--16.77--
Xencor Inc168.34m-126.09m1.37bn280.00--2.04--8.14-2.10-2.102.7910.960.1872--8.36601,207.10-14.04-3.70-15.30-4.12-----75.00-15.92----0.0304--2.2832.90-128.50--18.36--
Day One Biopharmaceuticals Inc0.00-188.92m1.38bn155.00--3.97-----2.37-2.370.003.970.00----0.00-52.11---55.65--------------0.00-------32.87------
Ocular Therapeutix Inc58.44m-80.74m1.38bn267.00--11.74--23.68-0.9939-0.99390.72330.79270.29122.472.46218,883.90-40.23-46.70-48.19-54.1890.9689.36-138.15-228.656.59-6.570.4512--13.4996.60-13.65--26.37--
Soleno Therapeutics Inc0.00-38.99m1.39bn33.00--8.62-----2.97-2.970.004.970.00----0.00-37.64-53.90-41.40-61.85------------0.00-------62.00------
Kiniksa Pharmaceuticals Ltd270.26m14.08m1.41bn297.00124.983.2185.945.220.15990.15993.746.230.54821.2713.00909,962.902.86-16.493.22-18.7287.64--5.21-53.643.85--0.00--22.74---92.32---52.35--
Data as of Mar 28 2024. Currency figures normalised to Xencor Inc's reporting currency: US Dollar USD

Institutional shareholders

72.78%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 202310.07m16.55%
PRIMECAP Management Co.as of 31 Dec 20238.90m14.62%
The Vanguard Group, Inc.as of 31 Dec 20236.63m10.89%
EcoR1 Capital, LLCas of 31 Dec 20235.28m8.68%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 20233.36m5.52%
SSgA Funds Management, Inc.as of 31 Dec 20233.33m5.47%
Fidelity Management & Research Co. LLCas of 31 Dec 20232.56m4.21%
Armistice Capital LLCas of 31 Dec 20231.50m2.46%
T. Rowe Price Investment Management, Inc.as of 31 Dec 20231.35m2.22%
Geode Capital Management LLCas of 31 Dec 20231.31m2.16%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.